Top 5 Eye Care Apps for Primary Care Providers

Weekly Dose Podcast: FDA Breakthrough in Acromegaly, Alcohol–Dementia Risk Clarified, Tirzepatide in Youth T2D, Precision Mood Gains, and Major Contraception Practice Insights

A new review examines whether neuromodulation techniques may help address excessive daytime sleepiness across neurologic and psychiatric conditions.

November 19th 2025

Fezolinetant Shows Real-World Benefits for Menopausal Symptoms: Daily Dose

Topics include new findings on oral acromegaly therapy, alcohol and dementia risk, tirzepatide in youth T2D, precision mood care, and LARC outcomes.

Weekly Dose Podcast: New Insights on Colonoscopy Adherence, rt-CGM in GDM, Semaglutide Effects, Parent Vaccine Views, and MI Causes

Your daily dose of the clinical news you may have missed.

November 13th 2025

Retatrutide Achieves Up to 28.7% Weight Loss and Marked Knee Pain Reduction in Phase 3 TRIUMPH-4 Trial

Topics include rideshare support for colonoscopy, rt-CGM benefits in GDM, semaglutide and food noise, vaccine views, and MI etiology.

Two Global Phase 3 Trials Confirm Efficacy of Rocatinlimab for People With Moderate-to-Severe Atopic Dermatitis

Both doses of the GLP-1, GIP, glucagon triple agonist (9- and 12-mg) met all primary and key secondary endpoints and reduced CV risk factors as well, Eli Lilly said.

Opportunities and Limits of Neuromodulation for Excessive Daytime Sleepiness: Highlights of a Narrative Review

Two global phase 3 trials found rocatinlimab significantly improved EASI-75 and vIGA-AD outcomes at 24 weeks in people with moderate-to-severe AD with acceptable safety.

Related Content

Weekly Dose Podcast: FDA Breakthrough in Acromegaly, Alcohol–Dementia Risk Clarified, Tirzepatide in Youth T2D, Precision Mood Gains, and Major Contraception Practice Insights

A new review examines whether neuromodulation techniques may help address excessive daytime sleepiness across neurologic and psychiatric conditions.

November 19th 2025

Fezolinetant Shows Real-World Benefits for Menopausal Symptoms: Daily Dose

Topics include new findings on oral acromegaly therapy, alcohol and dementia risk, tirzepatide in youth T2D, precision mood care, and LARC outcomes.

Weekly Dose Podcast: New Insights on Colonoscopy Adherence, rt-CGM in GDM, Semaglutide Effects, Parent Vaccine Views, and MI Causes

Your daily dose of the clinical news you may have missed.

November 13th 2025

Retatrutide Achieves Up to 28.7% Weight Loss and Marked Knee Pain Reduction in Phase 3 TRIUMPH-4 Trial

Topics include rideshare support for colonoscopy, rt-CGM benefits in GDM, semaglutide and food noise, vaccine views, and MI etiology.

Two Global Phase 3 Trials Confirm Efficacy of Rocatinlimab for People With Moderate-to-Severe Atopic Dermatitis

Both doses of the GLP-1, GIP, glucagon triple agonist (9- and 12-mg) met all primary and key secondary endpoints and reduced CV risk factors as well, Eli Lilly said.